Fertility 2018, the joint Conference of the Association of Clinical Embryologists, British Fertility Society and the Society for Reproduction & Fertility, returns to the Arena Convention Centre (ACC), Liverpool. The ACC is situated on the Kings Waterfront, close to the Grade 1 listed Albert Dock and the World Heritage site at Pier Head.
Now the largest of its kind in the UK, the conference will bring together over 700 fertility experts for a three day programme on the latest scientific and clinical developments and updates in fertility, sexual health and reproductive biology.
Planer will be showcasing our recently launched CT37stax™ Multi Chamber Benchtop Incubator, our DATAssure™ alarm and monitoring system and our Shiplogs3™ temperature data logger. To find out more, please come and see us on stand 13.
For further information
Fertility 2018 is the 11th Joint Conference of the following UK Fertility Societies. Further information about these societies can be found at:-
Planer Incubator Management Software (PIMS) is an easy-to-use management software suite for Planer BT37, CT37stax™ and INC-A20 benchtop CO2 incubators. The software, which can be downloaded from the Planer website, is free for all Planer incubators users.
The intuitive and user friendly suite provides the convenience of controlling multiple Planer CT37stax™ units as well as monitoring key parameters of multiple INC-A20 and BT37 incubators connected to your existing IT network with access from any connected PC.
Why use PIMS?
PIMS is free to download - all you need to do is visit any incubator page on the Planer website for details. Alternatively, please feel free to contact the sales team for more details.
Planer recently installed the world’s first DATAssure™ alarm and monitoring system in an ART clinic in a private hospital just outside London. The system comprises of 40 sensor points monitoring their incubators' temperature and CO2 levels, their storage dewars’ temperature and liquid nitrogen levels and their cryo bank's oxygen levels.
The DATAssure™ is the next generation alarm and monitoring system to replace the original Planer DATAcentre system and was launched at ESHRE in July. Part numbers and prices for the European 433 MHz version of the DATAssure™ system will be released in the price lists shortly with the worldwide 2.4Ghz version to follow in early 2018.
The DATAssure™ system provides all of the features you would expect from a modern monitoring system, including a clear colour touchscreen, 12 hour battery back-up and up to 10 years plus data storage. Up to 150 wireless sensors monitoring a wide variety of different environmental and equipment parameters can be connected to the system providing truly independent monitoring throughout the laboratory.
For more details on the new DATAssure™ system, please contact the sales team at Planer.
A bioartificial liver is used as an extra-corporeal organ which is designed to supplement the function of the liver in patients with acute liver failure. This is to allow time to find a suitable donor or for the liver to undergo self-repair. The University College London's bio artificial liver consists of liver cells encapsulated in alginate, which have formed spheroids grown in a fluidised bed bioreactor. For patients with acute liver failure an “off-the-shelf treatment needs to be available and to that end Mo Awan, Joana Mendonca-Silva, Eloy Erro and the team have endeavoured to develop a cryopreservation protocol to preserve a large biomass and recover it after thawing.
The aim of recent research, published at the Society for Low Temperature Biology meeting in Cambridge 2017, was to see whether the rate at which the biomass is warmed affects post thaw recovery. The results suggested slow thawing produces better post thaw recovery than when the same volume biomass was fast thawed. This would infer that slow thawing aids recovery of cryopreserved spheroids. The cooling rates for two samples was not the same though: during one cooling the cryo bag cooled faster than the cryo bottle and remained at -50°C for longer. This likely resulted from better heat transfer in bags, and allowed dissipation of latent heat of ice nucleation. This may potentially alter ice crystal formation and have a negative effect on the biomass. Slower warming may also allow less stressful water re-equilibration in the spheroids as the ice melts.
UCL's bio artificial liver team are at the Institute for Liver and Digestive Health, UCL Medical School, Royal Free Campus, London NW3 2PF in the UK
A PDF of the full poster is available here
A recent paper sets out the options for cryopreservation of cell therapies now and gives pointers to future research. Prof Barry Fuller et al summarise (Cell and Gene, Therapy Insights, June '17) the applications of cryopreservation technologies to cellular therapeutics and their delivery. The ability to hold products in readiness for logistical, regulatory or potency reasons is highlighted and it usually involves cryopreservation. However, cryopreservation itself poses biological and biophysical challenges to living cells that need to be understood in order to apply the low temperature technologies to their best advantage.
The review sets out the history of applied cryopreservation, current understanding of the various processes involved in storage at cryogenic temperatures, and the challenges for the reliable uses of cryopreservation within cell therapy. The authors include observations on slow freezing: "Successful cryopreservation was also found to be influenced by the kinetics of the cooling process itself. As often practiced today, slow cooling (where slow as a relative term applies to cooling rates of between about -0.3 Deg C min-1 and -2 Deg C min-1) were found by empirical observation to relate to good success." And in another section: " ....as other cell therapies have entered the arena within the broad area of hematopoietic stem cell replacement, slow cooling cryopreservation has maintained its beneficial role, but with some addition to detail in terms of protocol management."
To read the full article
A new article in Cell and Gene Therapy Insights neatly sets out the advances in procurement and storage in the umbilical cord blood and tissue bio processing field. The paper by Dr Qasim Rafiq of London's UCL, Kate Sneddon and members of Biovault Technical Ltd, a leading tissue bank in the UK, looks at regenerative medicine related to both autologous and allogeneic therapeutic applications and describes the current challenges and how these may be met to augment translation and use of therapeutics.
Cord blood and tissue banking is increasingly popular because of the stem cells they contain and the clinical research associated with such material is advancing. Umbilical cord blood (UCB) is a source of hematopoietic stem cells (HSCs) and is clinically applied for the reconstitution of hematopoiesis. Umbilical cord tissue (UCT) contains mesenchymal stem cells (MSCs) that have been widely investigated for applications in tissue restoration and repair, and the treatment of immune mediated disorders.
UCB is defined as the blood that remains in the umbilical cord and placenta following neonatal delivery, and UCT as the cord itself. Both tissues are procured immediately after birth in a process not deleterious to mother or child. In fact, banking of these tissues may confer future health benefits to the corresponding child or immediate family as they potentially comprise an exact or partial human leukocyte antigen match, reducing complications such as graft-versus-host disease upon transplantation. Additionally, both tissues may be applied in allogeneic models; UCT MSCs are immune evasive and donor-recipient mismatches can be well tolerated in transplantation.
The potential applications of UCB HSCs and UCT MSCs in both autologous and allogeneic therapeutics has encouraged the coexistence, sometimes within the same organization, of two tissue storage models. Parents may choose to publicly bank their UCB for use for any patient, or store privately for the event of disease in the immediate family.
Over 750,000 UCB units are thought to be banked publicly worldwide, with over 4 million banked in private family storage arrangements. There are a considerable number of clinical trials concerning the application of UCT MSCs, creating demand for UCT processing strategies that maintain the viability, efficacy and safety of derived therapeutics.
The authors conclude that to elucidate strategies that are optimal with respect to cell functionality, patient outcomes and cost to be developed, UCB volume reduction, antibiotic-free bio processes, low DMSO in cryopreservation media, and improved antimicrobial strategies may aid the readiness of UCB and UCT banking.
For further information
Citation: Cell Gene Therapy Insights 2017;3(6), 489-508. Published: Aug 4 2017
You can read the whole article by registering (free) at Cell and Gene Therapy Insights online
Planer freezers at Biovault
Planer is pleased to announce the launch of the ShipsLog3™ temperature data logger. The new ShipsLog3™ is the latest edition of the well-established ShipsLog™ product range which has been providing protection to samples inside vapour and dry shippers for over 15 years. The ShipsLog3™ temperature data logger provides an accurate and downloadable temperature history of your vapour shipper throughout its transit.
There are two versions of ShipsLog3™ available;
Both versions of the ShipsLog3™ are fitted with red and green status LEDs for immediate recognition of the logger status.
*EasyLog software or EasyLog CFR software required dependent on model of ShipsLog3™
+Sold separately (not compatible with 21CFR version)